Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment ...

They work at Vertex’s cystic fibrosis research center in San Diego and have collaborated for more than 20 years on four game-changing drugs that have won approval since 2012. “However ...

The number of people living with CF worldwide is now 105,000, up from 70,000 in 2012, according to estimates from US ...

The drug, Ivacaftor (Kalydeko), is the first drug designed to treat the basic defect in cystic fibrosis. It was originally approved for adults, then sequentially over several years for older and ...

The drug, Ivacaftor (Kalydeko), is the first drug designed to treat the basic defect in Cystic Fibrosis. It was originally approved for adults, then sequentially over several years for older and ...

Kalydeco, already approved for patients as young as 1 month old in the US and UK, is now available to babies that young throughout the Europe Union.

Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic ...

A “groundbreaking” drug which targets the underlying cause of cystic fibrosis has been shown to be safe and effective in newborns aged four weeks and above. Until now, Ivacaftor - sold under ...

Ivacaftor, also known as Kalydeko, has already been approved for adult and child cystic fibrosis patients, but this is the first time the drug has been proven safe in babies aged four weeks and up.

Currently, it is approved for babies aged four months ... a landmark study which supports use of a ground-breaking cystic fibrosis drug in infants from four weeks of age. Irish siblings Kara ...

The drug, Ivacaftor (Kalydeko), is the first drug designed to treat the basic defect in Cystic Fibrosis. It was originally approved for adults, then sequentially over several years for older and ...